chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous report as received from a medical assistant refers to three patients of unkown age and gender. The patients' medical histories, concurrent conditions and concomitant medications were not reported. On unknown dates three patients were vaccinated with doses of improperly stored GARDASIL (dose, route of administration, lot number were not reported). No adverse events were reported. This is one of several reports from the same reporter. Additional information has been requested.
some runny nose last couple of days but WITHOUT fever or cough; sick; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from medical information team for a program. The reporter is the patient.  A male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 1, single for covid-19 immunization. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: RHINORRHOEA (non-serious) with onset 11Apr2021, outcome "unknown", described as "some runny nose last couple of days but WITHOUT fever or cough"; ILLNESS (non-serious) with onset 11Apr2021, outcome "unknown", described as "sick". Relevant laboratory tests and procedures are available in the appropriate section.  Additional Information: The consumer was scheduled to take his second shot of the PFIZER-BIONTECH COVID-19 VACCINE this evening and he had some runny nose last couple of days but without fever or cough. He also did a rapid test and came back negative for COVID19 virus just to be sure. He just wanted to know and he is seeking guidance as to whether he should get his second shot. Also, consumer mentioned that it was 30 days since his first shot. Caller called in on behalf of her son, who is about to receive his 2nd dose of our COVID-19 vaccine tomorrow 13Apr2021 but might not be able to attend it since (withheld) has been sick since yesterday 11Apr2021. (Withheld) is not sure when did receive his 1st dose but she thinks it was 3 weeks ago.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Patient CAME INTO THE PHARMACY COMPALING OF DIARREA THAT STARTED THE MORNING AFER THE VACCINE AND CONTINUES TO TODAY
Tiredness; This is a spontaneous report from a contactable consumer (Patient) or other non HCP  A 52-year-old (non-pregnant) female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Formulation: Solution for injection, Lot number: EN6207, Expiration Date: not reported) via an unspecified route of administration in right arm on 22Mar2021 (at the age of 52-year-old) as dose 1, single for COVID-19 immunization. Medical history included sleep apnoea syndrome, type 2 diabetes mellitus, high blood pressure, depression, high cholesterol.The patient's concomitant medications were not reported. Patient did not received any other vaccine in four weeks. Patient received other unspecified medications in two weeks. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. There were no known allergies. The patient experienced tiredness on 22Mar2021. The patient underwent lab tests and procedures which included sars-cov-2 test (Nasal Swab) negative COVID-19 NAT on 01Jun2021. The outcome of the event was unknown.
Patient stated that after receiving vaccine, she was unable to lift left arm up the next day. Stated that she noted tingling in her fingers. She went to her physician and was given FLEXERIL and NAPROSYN and was told not to work for two days. Was asked to return if symptoms continue.
Heart palpitations and fatigue after 1st injection in March. Increase in frequency in May, after the 2nd injection.
I would not have submitted but my symptoms back in February were similar Covid-19. Headache, woke with  deep body chills in my core and shaking that took a several minutes to calm, mucous build-up, sore throat, fatigued (I was bed ridden while ill, my partner waited on me and I road it out like a flu or bad cold) )extreme vertigo followed about a week after, then I wrote the doctor in a portal for medication for spinning, nausea. She prescribed meclizine which I needed into early March 2020. Also in March, I was prescribed Trulicity which I have stopped. I have had one more deep chill that passed quickly in April. Fatigued linger, sore throat came and went several times throughout March and April. I am feeling much better this month of May. I am not one to ever go to the doctor for a basic cold or a rare flu caught by me. I mainly see the health center for follow-up diabetic and hypertension. Than you.
pt recvd vax; local swelling/ pain w/ neuritis in ulnar N;
No adverse effects; a patient was administered a dose of improperly stored VARlVAX; This spontaneous report was received from a nurse referring to a patient of unknown age and gender. Information about medical history, concurrent conditions, drug reactions/allergies and concomitant therapies was not provided.  On 17-OCT-2019, the patient was vaccinated with improperly stored dose (product storage error) of varicella virus vaccine live (oka/merck)(VARIVAX) (lot # S015460, expiration date 20-MAY-2021; vaccine dosage detail not reported) subcutaneously for prophylaxis which was reconstituted with sterile diluent, it could not be determined if the sterile  diluent was properly stored. Temperature was - 11 .5 degree Celsius for 76 hours. There was no previous temperature excursion. No adverse effects were reported. No product quality complaints (PQC) was reported. Data logger was involved.
about 5 minutes after getting the shot pt said her hand was red and swollen. she stayed for about 30 minutes and said it was better
Patient noted rash on trunk, flank and buttocks area approximately 48-72 hours after vaccine was given. No swelliing of injection site. Denies s/s allergic reax or anaphylaxis.
Eyes swollen; lids puffy and red, red circles around each eye; lids puffy and red, red circles around each eye; yellow jaundice look below each eye in a little pouch filled with fluid; itchy eyes; skin on eye lids peeled off; yellow jaundice look below each eye in a little pouch filled with fluid (this jaundice look with pouch disappeared within 5 -6 days from receiving 1st shot).; This is a spontaneous report from a contactable female other healthcare professional reported for herself that 78-year-old female patient received first dose bnt162b2 (Solution for injection, pfizer (Batch/Lot Number: EL9265)) via an unspecified route of administration, administered in Arm Left on 28Jan2021, 16:45 as single dose for covid-19 immunisation. Medical history included myocardial infarction from 2014 to an unknown date In good health - Heart Attack 2014 , drug hypersensitivity from an unknown date and unknown if ongoing known_allergies: Sulfa drugs. The patient historical vaccine bnt162b2 (Solution for injection) on 28Jan2021 Start Date/Time: [Pfizer Lot EN6198] 19Feb2021 09:45 AM, left arm for covid-19 immunisation. Facility most recent COVID-19 vaccine was administeredin Doctor's office/urgent care. The patient was not received any other vaccines within 4 weeks prior to the COVID vaccine. On 01Feb2021 07:00 AM, Eyes swollen, lids puffy and red, red circles around each eye, itchy eyes, skin on eye lids peeled off, yellow jaundice look below each eye in a little pouch filled with fluid (this jaundice look with pouch disappeared within 5 -6 days from receiving 1st shot). Other eye condition remains. The event Yellow ocular coloring was recovered in 2021 and other events not recovered.
Patient was administered vaccine on 3/25/2022 that expired on 3/24/2022.
Patient reported he has history of fainting after getting a ceftriaxone injection years ago. We talked through the possible scenarios and proceed with the vaccine with his partner next to him for support. Patient sat down after vaccine for 5 minutes and his partner came up to notify me that patient was not feeling well. I went to check on him and saw that he was still alert, conscious and able to have a conversation. However, he appeared pale, uncomfortable and sweating. I went to get him some paper towel and went I came back he said he felt nauseous and wanted to head toward the restroom. I urged him to stay seated and I went to get him a plastic bag. By the time I came back, he already started vomiting tan fluid on the floor. Patient vomit for lest than one minute and felt better. He stayed for observation for another 20 minutes and felt well and left.
severe fatigue; joint pain; headache; stomachache; nausea; felt like oncoming flu symptoms; I got no sleep; This case was reported by a consumer via interactive digital media and described the occurrence of influenza-like symptoms in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Concomitant products included COVID-19 VACCINE (COVID 19 BOOSTER).   On 19th March 2022, the patient received the 2nd dose of Shingles vaccine. In March 2022, less than a day after receiving Shingles vaccine, the patient experienced sleeplessness. On 20th March 2022, the patient experienced influenza-like symptoms, fatigue, joint pain, headache, stomach pain and nausea. On an unknown date, the outcome of the influenza-like symptoms, sleeplessness, fatigue, joint pain, headache and nausea were recovered/resolved and the outcome of the stomach pain was unknown.   It was unknown if the reporter considered the influenza-like symptoms, sleeplessness, fatigue, joint pain, headache, stomach pain and nausea to be related to Shingles vaccine.     Linked case(s) involving the same patient:  US2022AMR052525   Additional Information: GSK Receipt Date: 22-MAR-2022 Reporter's Comment:  This case was reported via interactive digital media.  The patient received second shot on Saturday and asked the pharmacist if there were any side effects and he said just injection site pain.  The patient received first shot with Covid booster and was not sure when just the shingles shot.  Though patient's actual side effects were nothing compared to what shingles like but the night of the shot patient got no sleep.  On the morning patient had severe fatigue, joint pain, head or stomachache and slight nausea.  The reporter mostly felt like oncoming flu symptoms and on the reporting day, patient felt absolutely great.  Additional supportive information The follow-up would not possible as no contact details were available.; Sender's Comments:  US-GLAXOSMITHKLINE-US2022AMR052525:same report, 1st dose
Information has been received from a registered nurse referring to an unspecified patient of unknown age and gender. On 06-AUG-2015 the patient was vaccinated with a dose of PROQUAD (Merck) (lot # K020750, expiration date 30-APR-2016) and a dose of VARIVAX (Merck) (lot # K009758, expiration date 09-JUL-2016) (overdose). No adverse experiences were reported. The outcome was unknown. Additional information has been requested.
Patient reports lightheadedness, clammy skin. Improved when supine. Patient has history of vasovagal reaction with vaccine.
Couple days after slight pain in arm at injection site. Three days after, had bumps on my head / scalp that were sensitive to the touch and a mild headache started. The headache continually got worse , starting evening of Tues Feb 9 to Thurs afternoon Feb 11 was a constant severe headache. Could not sleep, got some relief by placing cold ice pack on back of neck and on forehead.  Headache is now subsiding slowly.  No energy.
Fever asthma exacerbation, chest tightness for a few days. BENADRYL helped symptoms. Developed nausea and diarrhea on 10/7/16 and BENADRYL helped.
Heplisav-B Administered While Lactating; Initial Report Received on 11-APR-2023.  A registered nurse reported that a female (age, race, and ethnicity not provided) received HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization and the patient is lactating/breastfeeding.  No relevant medical history was reported.    No relevant concomitant medications were reported.    On an unspecified date, the patient received a dose of HEPLISAV-B (Lot number, expiration date, and NDC number, route, and site not reported).  On an unspecified date, after having been vaccinated with HEPLISAV-B, the patient was reported to be lactating and breastfeeding.  No additional information was reported.    Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.
within 2 days of 1st vaccine @ 1/18/21 noted blood in stool & then within 2 days of second vaccines given on 03/18/21 The same. Still feeding well however after 2nd set imz there was blood in alternating diapers a couple times. This limited milk protein intake from mothr.
pt recvd vax 17NOV93 pt had uncontrollable fever approx 12 hrs p/vax; fever as high as 103 R w/twitching; dx w/sz activity;
This spontaneous report was received from a medical assistant and refers to a 4-month-old patient of unknown gender. No information about the patient's pertinent medical history, concomitant medications, drug reactions or allergies was provided. On 17-MAY-2016, the patient was vaccinated with an improperly stored dose of PEDVAXHIB lot # L014429 and expiration date 15-MAR-2018 (dose and route of administration were not reported). The vaccine underwent temperature excursion of 1 degree Celsius for 158 total cumulative hours, which was detected by a data logger. There was no previous temperature excursion. No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
Interchange of vaccine products; Revaccination with different COVID-19 vaccine; sweating; feeling absolutely terrible; headache; This spontaneous case was reported by a consumer and describes the occurrence of HYPERHIDROSIS (sweating), FEELING ABNORMAL (feeling absolutely terrible), HEADACHE (headache), INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) and COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine) in a 65-year-old male patient who received mRNA-1273.815 (SPIKEVAX 2023-2024) (batch no. ASKU) for COVID-19 prophylaxis.    Co-suspect product included non-company product INFLUENZA VACCINE for Influenza immunisation.    The patient's past medical history included COVID-19 (2 months ago). Previously administered products included for COVID-19 immunisation: Johnson and Johnson (had 2 Johnson and Johnson COVID-19 Vaccines previously.). Past adverse reactions to the above products included No adverse event with Johnson and Johnson. Concurrent medical conditions included CLL.   On 30-Oct-2023, the patient received dose of INFLUENZA VACCINE (unknown route) 1 dosage form. On 30-Oct-2023 at 10:30 AM, the patient received third dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. On 30-Oct-2023, the patient experienced HYPERHIDROSIS (sweating), FEELING ABNORMAL (feeling absolutely terrible) and HEADACHE (headache). On an unknown date, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) and COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, HYPERHIDROSIS (sweating) and HEADACHE (headache) had not resolved and FEELING ABNORMAL (feeling absolutely terrible), INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) and COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine) outcome was unknown.        For mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications were not reported.   Reported that patient was feeling absolutely terrible. He has been in bed since Monday night. He was sweating, had headache and he just felt terrible. His oncologist recommended to get the vaccine. Patient had lot of water. He felt like he had COVID-19 again.
This is a spontaneous report from a contactable physician via a sales representative. This Physician reported for similar event for 2 Patients. This is 1st of 2 report. An adolescent patient of an unspecified ethnicity and gender received first dose of TRUMENBA, via an unspecified route of administration on an unspecified date at single dose for immunization. The patient medical history was not reported. The patient's concomitant medications were not reported. The patient experienced terrible muscle pain on an unspecified date with outcome of unknown. Sender's Comments: Linked Report(s): US-PFIZER INC-2017453975 same reporter/drug/event, different patient.
1 week post vax, the child developed a fever then apthous ulcers in his mouth.
Extreme vertigo; unable to walk with any steadiness.  Dizziness has continued for the 10 days since.
Information has been received from a mother concerning her approximately 44-week-old son who was vaccinated with the first (at 44-46 weeks of age) and second doses (at 55 weeks of age) of Rotateq. It was unknown if medical attention was sought. No symptoms were reported. Additional information has been requested.
Continuous elevated heart rate; higher resting heart rate than average; constantly feeling winded from the simplest things that used to not affect me; my heart just didn?t feel right, slightly fluttery and like it was working harder than it should be. Symptoms lasted about 3 weeks before returning to normal
They give me the pfizer vaccine at 11 am, after 1 or 2 hours I felt my jaw set hard for a few seconds, then I breathed and passed. Then at night of the same day around 6 or 7pm I felt itching in my belly and after a second step. The next day when I ate some food my tongue would itch and pass. I do not know if what I felt is one of the adverse effects or is simply not related to the vaccine. I would like to know because I do not know whether to receive the second dose. What worries the most is the hardness of my jaw and the itchiness that I felt. I would appreciate an answer please.
pt recvd vax approx 20 to 30 yrs old & was vaxed 4 doses of MMR & lab eval revealed neg titers; No further details were provided;
Patient began to cough consistently and was unable to stop coughing.  Patient said yes to having a difficult time breathing.  Pulse ox was maintained at 98% on room air and heart rate was 130-150.  Mom was at bedside.  Pediatrician, Dr. , was called.  0.3mg Epipen was administered via right thigh.  Coughing began to slow down and patient's pulse ox maintained at 98%.  Patient was transferred via wheelchair to emergency room in the same building for continued monitoring.
Information has been received from a physician concerning an 82 year old female with metastatic breast cancer on chemotherapy, coronary disease, diabetes, chronic kidney disease and hypertension who on 30-APR-2007 was vaccinated with a dose of Zostavax. Concomitant therapy included OXYCONTIN, hydrochlorothiazide, glipizide, omeprazole, PERCOCET, lisinopril (manufacturer unknown), NORVASC, LYRICA, LIPITOR, citalopram, calcium (unspecified), HERCEPTIN and paclitaxel. On approximately 04-MAY-2007 the patient developed a rash which was cutaneous eruptions of zoster on her abdomen and perivaginal area. Unspecified medical attention was sought. The patient was treated with famcyclovir and the rash was getting better. There were no laboratory tests performed. There was no product quality complaint involved. Additional information has been requested.
tip of tongue numb; Metallic taste; lower left lip felt swollen; This is a spontaneous report from a contactable other health care professional (patient). A 41-year-old female patient started to receive BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number EL1284 and expiration date not provided), via an unspecified route of administration (Right arm) first dose on 02Jan2021 10:30 at single dose for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. On 02Jan2021, the patient experienced metallic taste, lower left lip felt swollen, and tip of tongue numb. The patient was treated with Injection 50 mg Benadryl L thigh. The outcome of the events was recovered in Jan2021. Facility where the most recent COVID-19 vaccine was administered in Workplace clinic. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Since the vaccination, the patient did not tested for COVID-19.
Information has been received from a physician concerning a 72 year old male patient with mild myelodysplastic syndrome previously treated with transfusions who on approximately 19-DEC-2011 ("one month ago"), was vaccinated with ZOSTAVAX (Merck) (dose, route and lot number not reported). The patient was instructed by his hematologist to get zoster vaccine live and than wait 1 month to start chemotherapy for the mild myelodysplastic syndrome. On approximately 5-JAN-2012 ("two weeks ago"), the patient experienced left flank pain. The patient was instructed to use a heating pad for 3-4 days. The patient returned to the office on 16-JAN-2012 in which the physician saw 1 large blister that was partially open and 4 large blisters that were closed. The patient was in more pain. The patient was diagnosed with shingles. The patient would be seen in the office 20-JAN-2012. At the time of the report the outcome of the patient was unknown. Follow up information has been received from a physician concerning a 77 year old (previously reported as 72 year old) patient with ASCVD, Type II DD, DJD, elevated cholesterol, PVD, AAA, glaucoma and a history of chickenpox in childhood and no recent exposure to chickenpox or herpes zoster who on 16-DEC-2011, was vaccinated with ZOSTAVAX (Merck) (0.65 ml, left arm, route not reported (lot number 671021/0747AA). Concomitant therapy included LASIX, GLUCOPHAGE, IMDUR, metoprolol, simvastatin (manufacturer unknown), GLUCOTROL XL, lisinopril, NIASPAN, timolol maleate 0.5% and TRAVATAN 0.02%. The physician reported that on 16-JAN-2012, the patient developed herpes zoster and pain from left back to abdominal. The patient had blisters. Patient used a heating pad himself for pain before known diagnosis. Dermatome involved L2-3. A lesion sample was collected on 20-JAN-2012. The sample was taken from a vesicular lesion. At the time of the report the patient was unknown. The patient was enrolled in the program to identify if a particular strain is present and if it is present, to identify if it is associated with the wild-type (WT) strain or with the Merck vaccine strain. Follow up information has been received from a physician concerning a patient, accountant, with mild TR, gallstones and a history of s/p CABG & R carotid endarterectomy and s/p fempopbypass and with no illness at the time of vaccination who on 16-DEC-2011, was vaccinated with the first dose of ZOSTAVAX (Merck). The physician reported that on 16-JAN-2012, the patient developed pain requiring pain meds with intensity of 10 (most). Dermatome involved left L2-3, number of lesions about 10. There was no fever to the physician knowledge. There was no other systemic symptoms. No photo was taken. The physician reported that the patient was on NEURONTIN at that time and the pain was decreasing some. The physician considered reported adverse experiences to be disabling. The PCR was received from a university indicating vesicular specimen was negative for VZV. At the time of the report the patient was not recovered (also reported as recovered). Additional information has been requested.
Took oral Typhoid x 2 on 8/12-14. Developed rashes on both cheeks. On 8/15/2002 noticed more rashes on neck. On 08/16 she was advised to take Benadryl and hold off the 3rd and 4th Typhoid oral vaccine. On 8/20/2002 pt took the 3rd Typhoid. 8/21/2002 diarrhea x 9. Advised stop #4 vaccine. Take Imodium AD and fl.up with M.D.
Rapid heart rate and palpitations.  Resting heart rate increase.  Week after vaccination threw up.  2 weeks after vaccination I was admitted to hospital with Tachycardia and hypokalemia for three days.  Since then I am still experiencing high tee resting heart rate.